Clinical Cancer Research · 2006 · 91 citations · 24 references
MedicineOncologyPharmacologyCancer PharmacologyCellular PharmacologyMolecular OncologyMtor Inhibitor TherapyMultiple MyelomaPharmacodynamics Of Anticancer AgentsMtor InhibitionMtor SignalingMultiple Myeloma TherapyMyeloma Cell LinesPhosphatidylinositol 3-Kinase Akt SignalingPhosphatidylinositol 3-Kinase-akt PathwayPhosphatidylinositol 3-Kinase-akt SignalingPi3k-akt-mtor Signaling
PURPOSE: The phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin (mTOR) pathway and the heat shock protein family are up-regulated in multiple myeloma and are both regulators of the cyclin D/retinoblastoma pathway, a critical pathway in multiple myeloma. Inhibitors of mTOR and HSP90 protein have showed in vitro and in vivo single-agent activity in multiple myeloma. Our objective was to determine the effects of the mTOR inhibitor rapamycin and the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin (17-AAG) on multiple myeloma cells. EXPERIMENTAL DESIGN: Multiple myeloma cell lines were incubated with rapamycin (0.1-100 nmol/L) and 17-AAG (100-600 nmol/L) alone and in combination. RESULTS: In this study, we showed that the combination of rapamycin and 17-AAG synergistically inhibited proliferation, induced apoptosis and cell cycle arrest, induced cleavage of poly(ADP-ribose) polymerase and caspase-8/caspase-9, and dysregulated signaling in the phosphatidylinositol 3-kinase/AKT/mTOR and cyclin D1/retinoblastoma pathways. In addition, we showed that both 17-AAG and rapamycin inhibited angiogenesis and osteoclast formation, indicating that these agents target not only multiple myeloma cells but also the bone marrow microenvironment. CONCLUSIONS: These studies provide the basis for potential clinical evaluation of this combination for multiple myeloma patients.
24
Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma
P. Leif Bergsagel, W. Michael Kuehl, Fenghuang Zhan et al. · Blood · 2005 · 695 citations · Full text
Medicine, Cell Biology, Oncology +15